The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia.

Horiuchi, Kazutaka; Tsuboi, Narumi; Hattori, Tomotaka; Yoshida, Kazuhiro; Akimoto, Masao

doi:10.1272/jnms.66.382

Cited by 7 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…at 6 month and at end point in group B. Hence a significant decrease of post voidal urine volume in Group-B than Group-A at both follow up (p<0.001).Similar results were observed in another study showing reduction of PVR after using tamsulosin 0.4 mg 12 .…”

Section: Resultssupporting

confidence: 85%

Is Double Dose of Tamsulosin Monotherapy Superior to Combination of Conventional Dose of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia

Hussain¹,

Khan

Islam

et al. 2020

Bang J Urology

View full text Add to dashboard Cite

Background: The primary aim of the medical therapy for BPH is to improve quality of life by relieving the lower urinary tract symptoms and prevent complications. Objectives: To compare efficacy and safety of double dose of tamsulosin monotherapy with combination of conventional dose of tamsulosin and finasteride in symptomatic BPH. Methods: This was a prospective study carried out in the Department of Urology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh during the period of July 2005 to June 2006. Total 60 patients of 45-80 years of age were consequently selected according to inclusion criteria. After completion of baseline clinical evaluation and investigations, participants were divided into two groups, group A and group B. Group A were given tamsulosin 0.4 mg for 1 week. Then double dose of tamsulosin (0.8 mg) were given from 2nd week for 12 months. Group B were given tamsulosin 0.4 mg and finasteride 5 mg for the same duration. Efficacy was evaluated at 6 month and 12 month follow up visit and a comparison was made between them. During follow up each was observed for any adverse effect. The parameters monitored were International Prostate Symptom Score (IPSS), Maximum urine flow rate (Qmax), Post Voidal Residual Volume (PVR) and Prostate volume. Results : Both double dose of tamsulosin 0.8 mg and combination of conventional dose of tamsulosin 0.4 mg and finasteride 5 mg are effective in relieving symptoms of BPH but combination dose is superior to double dose monotherapy. Outcome parameters at end point follow up after 12 months showed significant improvement of IPSS (p<0.05), PVR(p<0.001), Q max (p<0.001) and prostate volume (p<0.001) in combination group than double dose group .The incidence of adverse events were also significantly less in combination group (p<0.05). Conclusion: Combination of conventional dose of tamsulosin with finasteride appears to have more efficacy and safety than double dose of tamsulosin in symptomatic BPH. Bangladesh Journal of Urology, Vol. 20, No. 2, July 2017 p.94-98

show abstract

Section: Resultssupporting

confidence: 85%

Is Double Dose of Tamsulosin Monotherapy Superior to Combination of Conventional Dose of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia

Hussain¹,

Khan

Islam

et al. 2020

Bang J Urology

View full text Add to dashboard Cite

show abstract

“…There have been many reports on the positive effects of TAM on the subjective symptoms and objective findings of LUTS/BPH, Horiuchi et al13 assessed nocturia by estimating the American Urological Association (AUA) symptom score; they found that a TAM dosage of 0.2 mg/day was effective in treating nocturia at 4 weeks after administration. We also performed a similar study using I‐PSS14 and confirmed the improvement in nocturia after TAM administration.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia

Yoshida

Inadome

Masunaga

et al. 2010

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Studies have demonstrated the efficacy of doxazosin, tamsulosin and terazosin in populations (n ¼ 27-205) including Korean, Japanese and Chinese men. [30][31][32][33][34][35] These studies used a dose of 0.2 mg tamsulosin, whereas the CombAT study used 0.4 mg, with no unexpected safety or tolerability issues compared to studies using the 0.2 mg dose. Efficacy of the 5ARI finasteride has also been studied in Asian men, demonstrating reduced prostate volume, and improvement in symptoms and Q max at 6 months and 1 year.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

Chung

Roehrborn

Siami³

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this doubleblind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5 mg dutasteride once daily, 0.4 mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (Po0.05), and numerically, but not statistically significantly, greater compared with dutasteride. Mean IPSS was reduced from baseline by 7.5 (±0.84) in the combination group, by 6.3 (±0.86) in the dutasteride group and by 4.5 (±0.78) in the tamsulosin group, resulting in respective mean IPSS at months 24 of 11.4 (±0.60), 12.7 (±0.70) and 14.3 ( ± 0.74). The adverse event profile was similar to that observed in the overall CombAT population, and drug-related adverse events were more common with combination therapy (26%) than with tamsulosin (15%) or dutasteride (9%). No unexpected adverse events emerged. In conclusion, in Asian men with moderate-to-severe lower urinary tract symptoms and an enlarged prostate, combination therapy achieved significantly greater improvements from baseline BPH symptoms, flow rate, quality of life, reduced prostate volume and improved treatment satisfaction compared with tamsulosin monotherapy.

show abstract

The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia.

Cited by 7 publications

References 12 publications

Is Double Dose of Tamsulosin Monotherapy Superior to Combination of Conventional Dose of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia

Is Double Dose of Tamsulosin Monotherapy Superior to Combination of Conventional Dose of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia

Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

Contact Info

Product

Resources

About